News For EXEL From The Last 14 Days Check below for free stories on EXEL the last two weeks.
There are 7 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 10, 2012
|
| 06:06 EDT |  | EXEL |
| theflyonthewall.com: | Exelixis 11M share Spot Secondary priced at $5.50 | | The deal size was increased to 11M shares from 10M shares. Goldman acted as lead book running manager for the offering. :theflyonthewall.com |
|
|
February 9, 2012
|
| 16:07 EDT | | EXEL |
|
|
February 8, 2012
|
| 16:17 EDT |  | EXEL |
| theflyonthewall.com: | Exelixis reports Q4 EPS 35c vs. consensus (11c) | | Reports Q4 revenue $93.3M vs. consensus $38.44M. 2010. This increase was primarily due to the recognition of revenue as a result of the acceleration of deferred license revenue and the receipt of a one-time termination fee in connection with the wind-down in December 2011 of a 2009 collaboration with Sanofi for the discovery of inhibitors of Phosphoinositide-3 Kinase. :theflyonthewall.com |
|
|
February 3, 2012
|
| 10:07 EDT |  | EXEL |
| theflyonthewall.com: | Corrected: Gappers reports | | The gapping stocks reports this morning included stocks that traded below $10. All other aspects of the stories remain the same. :theflyonthewall.com |
| | 10:01 EDT | | EXEL |
| | 06:02 EDT |  | EXEL |
| theflyonthewall.com: | Exelixis reports preliminary data from Phase 1b cabozanitinib trial | | Exelixis reported preliminary data from a cohort of heavily pretreated patients with metastatic refractory renal cell carcinoma participating in an ongoing phase 1b trial of cabozantinib. As of the January 18, 2012 data cut-off, 25 RCC patients were enrolled with 88% having received prior anti-VEGF therapy, 60% having received prior mTOR inhibitor therapy, and 52% having received ≥1 anti-VEGF and 1 mTOR therapy. Sixty-four percent of patients received ≥ 2 prior anti-cancer agents. Tumor regression was observed in 19 of 21 patients with ≥1 post-baseline assessment. Best overall response was determined per RECIST criteria with 7 of 25 patients showing a confirmed partial response. Importantly, PRs were observed in heavily pretreated patients, including 3 patients with 2-4 prior systemic therapies, and 2 patients with >4 prior systemic therapies. Thirteen additional patients had stable disease as their best response, and only a single patient demonstrated evidence of primary refractoriness to cabozantinib with a best overall response of progressive disease. The rate of disease control at week 16 for all 25 patients is 72%. :theflyonthewall.com |
|
|
January 31, 2012
|
| 06:53 EDT |  | EXEL |
|
|
|
Subscribe for More Information